Dr. Michael K. Yoon, M.D.
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- Albany Medical College of Union University (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 605
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: Albany Medical College of Union University
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
MA license 248987 · CA license A104744 · MA license 226070
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- Beth Israel Deaconess Medical Center Boston, MA
- Wentworth-Douglass Hospital Dover, NH
- Massachusetts Eye and Ear Infirmary - Boston, MA
Medical groups
- Harvard Medical Faculty Phys at Beth Israel Deaconess Med Ctr Inc (1,740 clinicians)
- Massachusetts Eye and Ear Associates, Inc (433 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 605
- Services billed
- 1,197
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient complete exam of visual system | 271 | 242 |
| Established patient problem focused exam of visual system | 269 | 254 |
| Exam of visual field with limited testing | 134 | 133 |
| New patient complete exam of visual system | 128 | 128 |
| New patient problem focused exam of visual system | 57 | 57 |
| Biopsy of eyelid | 51 | 44 |
| Repair of tendon of upper eyelid | 43 | 43 |
| Probing of nasal tear duct | 38 | 37 |
| Removal of growth of eyelid | 31 | 30 |
| Photography of content of eyes | 25 | 25 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Erythromycin (erythromycin base) Other prescribers in Boston, MA | 21 |
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Boston, MA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $18.13 in total to this clinician.
| Amgen Inc. | $18.13 |
|---|
| Food and Beverage | $18.13 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $1,638 in research payments for these studies, mostly to the institutions running them.
- A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, and Efficacy of AMG 732 in Healthy Subjects and Subjects With Moderate-to-Severe Active Thyroid Eye…
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.